KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Net Income towards Common Stockholders: 2018-2025

Historic Net Income towards Common Stockholders for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$32.0 million.

  • Esperion Therapeutics' Net Income towards Common Stockholders fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Net Income towards Common Stockholders is -$32.0 million, which was down 139.04% from -$13.4 million recorded in Q2 2025.
  • Esperion Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $58.2 million during Q1 2024, with a 5-year trough of -$90.9 million in Q1 2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$32.0 million (2025), whereas its average is -$27.8 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 192.46% in 2024, then slumped by 171.30% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$69.1 million in 2021, then rose by 17.69% to -$56.8 million in 2022, then decreased by 1.02% to -$57.4 million in 2023, then soared by 63.71% to -$20.8 million in 2024, then fell by 2.90% to -$32.0 million in 2025.
  • Its Net Income towards Common Stockholders was -$32.0 million in Q3 2025, compared to -$13.4 million in Q2 2025 and -$41.5 million in Q1 2025.